PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A. U. Kulikov, I. A. Komarov
Formato:	Artigo
Idioma:	Russo
Publicado em:	IRBIS LLC 2015-03-01
coleção:	Фармакоэкономика
Assuntos:	pharmacoeconomic analysis chronic obstructive pulmonary disease tiotropium bromide spiriva ipratropium bromide atrovent, budget impact analysis
Acesso em linha:	https://www.pharmacoeconomics.ru/jour/article/view/37
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!